Skip to main content
. 2023 Aug 30;15(17):4330. doi: 10.3390/cancers15174330

Table 4.

Safety profile in the first-line setting.

First-Line Setting, Regimen Group, No. (%)
NIVO + IPI
N = 39
NIVO1 + IPI3
N = 25
NIVO3 + IPI1 N = 14 p Value
Any treatment-related AE 28 (72) 18 (72) 10 (71) 1
AE Grade ≥ 3 13 (33) 12 (48) 1 (7) 0.013

Abbreviations: NIVO1 + IPI3, nivolumab 1 mg/kg + ipilimumab 3 mg/kg; NIVO3 + IPI1, nivolumab 3 mg/kg + ipilimumab 1 mg/kg; AE, adverse event.